(Q38232097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

meta-analysis

0 references

title

Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Vivaldo G da Costa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ariany C Marques-Silva

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Vitor G Floriano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

19 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

4885-4892

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

Dengue: a continuing global threat

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Economic and disease burden of dengue in Southeast Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

The causes and consequences of genetic variation in dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Immune response to dengue virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Prospects for a dengue virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Next-generation dengue vaccines: novel strategies currently under development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Dengue vaccines: recent developments, ongoing challenges and current candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Role of humoral versus cellular responses induced by a protective dengue vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Dengue vaccines: strongly sought but not a reality just yet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Blood pressure control by home monitoring: meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Bias in meta-analysis detected by a simple, graphical test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Explaining heterogeneity in meta-analysis: a comparison of methods.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Why sources of heterogeneity in meta-analysis should be investigated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Measuring inconsistency in meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

The case of the misleading funnel plot

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Development of Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

The necessity and quandaries of dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Critical issues in dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Identifying protective dengue vaccines: guide to mastering an empirical process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Evaluation of dengue virus strains for human challenge studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Challenges in the interpretation of dengue vaccine trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Flavivirus-induced antibody cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.07.008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25045816%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference